Report cover image

Cancer Pain Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319873

Description

The cancer pain market attained a value of USD 6.53 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 6.10%, to reach USD 11.81 Billion by 2034.

Cancer Pain Market Overview

Cancer pain can result from a tumor pressing on organs, nerves, or bones. It can also be caused by cancer treatments or surgery. The severity of pain can differ depending on factors such as the type of cancer and its stage. The rising prevalence of cancer necessitates the need for effective therapeutics to manage cancer pain. With the global burden of new cancer cases predicted to reach approximately 30 million by 2040 , the cancer pain market demand is anticipated to surge in the forecast period.

The increased impetus for research activities to address the growing need for cancer pain treatment solutions has bolstered market growth. Intensive research efforts are paving the way for potential therapeutics. According to a study published in BMJ Supportive & Palliative Care in May 2023,  medical cannabis was revealed to be safe and effective for treating cancer-related pain. Further, the use of medical cannabis reduced the use of opioids and other pain medications by almost 32%. Thus, the introduction of such products in cancer patients’ pain regimens is likely to augment the cancer pain market growth.

The market is also driven by the rising healthcare expenditure to treat cancer-associated pain as well as various initiatives and programs launched by the government to raise awareness regarding the condition. Moreover, the rising geriatric population with increased susceptibility to cancer pain will also help in the market growth.

Cancer Pain Market Segmentation

Cancer Pain Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type
  • Opioids
  
  • Fentanyl

    •   
  • Morphine

    •   
  • Others
    • Non-Opioids
      
  • Acetaminophen

    •   
  • Non-Steroidal Anti-Inflammatory Drug
    • Nerve Blockers
    Based on the drug type, the market is divided into opioids, non-opioids, and nerve blockers. Opioids such as fentanyl and morphine, among others, can help manage moderate to severe pain. Non-opioids like acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation and block pain signals without targeting opioid receptors. Nerve blockers help in blocking nerve signals responsible for pain transmission.

    Market Breakup by Indication Type
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Blood Cancer
    • Others
    The market segmentation by indication type includes lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The rising prevalence of different types of cancer is fueling the cancer pain market share.

    Market Breakup by Treatment Type
    • Immunotherapy
    • Chemotherapy
    • Targeted Therapy
    • Hormonal Therapy
    The market segmentation by treatment type comprises immunotherapy, chemotherapy, targeted therapy, and hormonal therapy. Each treatment type has unique mechanisms of action as well as potential side effects.

    Market Breakup by Region
    • United States
    • EU-4 and the United Kingdom
      
  • Germany

    •   
  • France

    •   
  • Italy

    •   
  • Spain

    •   
  • United Kingdom
    • Japan
    • India
    The market report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market which can be attributed to the rising geriatric population, the presence of an advanced healthcare system, and the increased prevalence of cancer in the region.

    Cancer Pain Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • Eli Lilly
    • HISAMITSU PHARMACEUTICAL CO., INC.
    • Aoxing Pharmaceutical Company, inc.
    • GRÜNENTHAL PHARMA GmbH & CO. KG
    • PFIZER INC.,
    • BIODELIVERY SCIENCES INTERNATIONAL, INC.
    • OREXO AB
    • Johnson and Johnson
    • Medtronic plc
    • Novartis AG
    • Glaxo SmithKline Plc
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

    Key Queries Solved in the Cancer Pain Market Report
    • How will the market landscape evolve in the coming years?
    • What are the major market trends influencing the market?
    • What are the major drivers, opportunities, and restraints in the market?
    • Which country is poised to lead the market share in the forecast period?
    • Which country is expected to experience expedited growth during the forecast period?
    • How do factors such as the rising prevalence of cancer impact market growth?
    • What are the different types of cancer pain treatments available in the market?
    • What are the latest advancements in cancer pain drug research and development?
    • What were the major drug approvals to manage cancer pain during the historical period?
    • Which segment has the major impact on the cancer pain market size?
    • What investments and funding are driving research and development in the market?
    • What are the key strategies adopted by leading pharmaceutical companies to gain market share?
    • How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Cancer Pain Overview
    3.1 Guidelines and Stages
    3.2 Pathophysiology
    3.3 Screening and Diagnosis
    3.4 Treatment Pathway
    4 Patient Profile
    4.1 Patient Profile Overview
    4.2 Patient Psychology and Emotional Impact Factors
    4.3 Risk Assessment and Treatment Success Rate
    5 Cancer Pain Epidemiology Analysis – 8MM
    5.1 8MM Epidemiology Scenario Overview (2018-2034)
    5.2 United States Cancer Pain Epidemiology Forecast (2018-2034)
    5.3 EU-4 and United Kingdom Cancer Pain Epidemiology Forecast (2018-2034)
    5.3.1 Germany Cancer Pain Epidemiology Forecast (2018-2034)
    5.3.2 France Cancer Pain Epidemiology Forecast (2018-2034)
    5.3.3 Italy Cancer Pain Epidemiology Forecast (2018-2034)
    5.3.4 Spain Cancer Pain Epidemiology Forecast (2018-2034)
    5.3.5 United Kingdom Cancer Pain Epidemiology Forecast (2018-2034)
    5.4 Japan Cancer Pain Epidemiology Forecast (2018-2034)
    5.5 India Cancer Pain Epidemiology Forecast (2018-2034)
    6 Cancer Pain Market Overview – 8MM
    6.1 Cancer Pain Market Historical Value (2018-2024)
    6.2 Cancer Pain Market Forecast Value (2025-2034)
    7 Cancer Pain Market Landscape – 8MM
    7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Cancer Pain Product Landscape
    7.2.1 Analysis by Drug Type
    7.2.2 Analysis by Indication Type
    7.2.3 Analysis by Treatment Type
    8 Cancer Pain Challenges and Unmet Needs
    8.1 Treatment Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Treatment
    10 Cancer Pain Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.3 Porter’s Five Forces Model
    10.4 Key Demand Indicators
    10.5 Key Price Indicators
    10.6 Industry Events, Initiatives, and Trends
    10.7 Value Chain Analysis
    11 Cancer Pain Market Segmentation – 8MM
    11.1 Cancer Pain Market by Drug Type
    11.1.1 Market Overview
    11.1.2 Opioids
    11.1.2.1 Fentanyl
    11.1.2.2 Morphine
    11.1.2.3 Others
    11.1.3 Non-Opioids
    11.1.3.1 Acetaminophen
    11.1.3.2 Non-Steroidal Anti-Inflammatory Drugs
    11.1.4 Nerve Blockers
    11.2 Cancer Pain Market by Indication Type
    11.2.1 Market Overview
    11.2.2 Lung Cancer
    11.2.3 Colorectal Cancer
    11.2.4 Breast Cancer
    11.2.5 Prostate Cancer
    11.2.6 Blood Cancer
    11.2.7 Others
    11.3 Cancer Pain Market by Treatment Type
    11.3.1 Market Overview
    11.3.2 Immunotherapy
    11.3.3 Chemotherapy
    11.3.4 Targeted Therapy
    11.3.5 Hormonal Therapy
    11.4 Cancer Pain Market by Region
    11.4.1 Market Overview
    11.4.2 United States
    11.4.3 EU-4 and the United Kingdom
    11.4.3.1 Germany
    11.4.3.2 France
    11.4.3.3 Italy
    11.4.3.4 Spain
    11.4.3.5 United Kingdom
    11.4.4 Japan
    11.4.5 India
    12 United States Cancer Pain Market
    12.1 Cancer Pain Market Historical Value (2018-2024)
    12.2 Cancer Pain Market Forecast Value (2025-2034)
    12.3 Cancer Pain Market by Drug Type
    12.4 Cancer Pain Market by Indication Type
    13 EU-4 and United Kingdom Cancer Pain Market
    13.1 Cancer Pain Market Historical Value (2018-2024)
    13.2 Cancer Pain Market Forecast Value (2025-2034)
    13.3 Germany Cancer Pain Market Overview
    13.3.1 Cancer Pain Market by Drug Type
    13.3.2 Cancer Pain Market by Indication Type
    13.4 France Cancer Pain Market Overview
    13.4.1 Cancer Pain Market by Drug Type
    13.4.2 Cancer Pain Market by Indication Type
    13.5 Italy Cancer Pain Market Overview
    13.5.1 Cancer Pain Market by Drug Type
    13.5.2 Cancer Pain Market by Indication Type
    13.6 Spain Cancer Pain Market Overview
    13.6.1 Cancer Pain Market by Drug Type
    13.6.2 Cancer Pain Market by Indication Type
    13.7 United Kingdom Cancer Pain Market Overview
    13.7.1 Cancer Pain Market by Drug Type
    13.7.2 Cancer Pain Market by Indication Type
    14 Japan Cancer Pain Market
    14.1 Cancer Pain Market Historical Value (2018-2024)
    14.2 Cancer Pain Market Forecast Value (2025-2034)
    14.3 Cancer Pain Market by Drug Type
    14.4 Cancer Pain Market by Indication Type
    15 India Cancer Pain Market
    15.1 Cancer Pain Market Historical Value (2018-2024)
    15.2 Cancer Pain Market Forecast Value (2025-2034)
    15.3 Cancer Pain Market by Drug Type
    15.4 Cancer Pain Market by Indication Type
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 India CDSCO
    16.1.4 JAPAN PMDA
    17 Patent Analysis
    17.1 Analysis by Type of Patent
    17.2 Analysis by Publication year
    17.3 Analysis by Issuing Authority
    17.4 Analysis by Patent Age
    17.5 Analysis by CPC Analysis
    17.6 Analysis by Patent Valuation
    17.7 Analysis by Key Players
    18 Grants Analysis
    18.1 Analysis by year
    18.2 Analysis by Amount Awarded
    18.3 Analysis by Issuing Authority
    18.4 Analysis by Grant Application
    18.5 Analysis by Funding Institute
    18.6 Analysis by NIH Departments
    18.7 Analysis by Recipient Organization
    19 Clinical Trials Analysis
    19.1 Analysis by Trial Registration Year
    19.2 Analysis by Trial Status
    19.3 Analysis by Trial Phase
    19.4 Analysis by Therapeutic Area
    19.5 Analysis by Geography
    20 Funding and Investment Analysis
    20.1 Analysis by Funding Instances
    20.2 Analysis by Type of Funding
    20.3 Analysis by Funding Amount
    20.4 Analysis by Leading Players
    20.5 Analysis by Leading Investors
    20.6 Analysis by Geography
    21 Partnerships and Collaborations Analysis
    21.1 Analysis by Partnership Instances
    21.2 Analysis by Type of Partnership
    21.3 Analysis by Leading Players
    21.4 Analysis by Geography
    22 Supplier Landscape
    22.1 Eli Lilly
    22.1.1 Financial Analysis
    22.1.2 Product Portfolio
    22.1.3 Demographic Reach and Achievements
    22.1.4 Mergers and Acquisitions
    22.1.5 Certifications
    22.2 HISAMITSU PHARMACEUTICAL CO., INC.,
    22.2.1 Financial Analysis
    22.2.2 Product Portfolio
    22.2.3 Demographic Reach and Achievements
    22.2.4 Mergers and Acquisitions
    22.2.5 Certifications
    22.3 Aoxing pharmaceutical company, inc.,
    22.3.1 Financial Analysis
    22.3.2 Product Portfolio
    22.3.3 Demographic Reach and Achievements
    22.3.4 Mergers and Acquisitions
    22.3.5 Certifications
    22.4 GRÜNENTHAL PHARMA GmbH & CO. KG
    22.4.1 Financial Analysis
    22.4.2 Product Portfolio
    22.4.3 Demographic Reach and Achievements
    22.4.4 Mergers and Acquisitions
    22.4.5 Certifications
    22.5 PFIZER INC.,
    22.5.1 Financial Analysis
    22.5.2 Product Portfolio
    22.5.3 Demographic Reach and Achievements
    22.5.4 Mergers and Acquisitions
    22.5.5 Certifications
    22.6 BIODELIVERY SCIENCES INTERNATIONAL, INC.,
    22.6.1 Financial Analysis
    22.6.2 Product Portfolio
    22.6.3 Demographic Reach and Achievements
    22.6.4 Mergers and Acquisitions
    22.6.5 Certifications
    22.7 OREXO AB
    22.7.1 Financial Analysis
    22.7.2 Product Portfolio
    22.7.3 Demographic Reach and Achievements
    22.7.4 Mergers and Acquisitions
    22.7.5 Certifications
    22.8 Johnson and Johnson
    22.8.1 Financial Analysis
    22.8.2 Product Portfolio
    22.8.3 Demographic Reach and Achievements
    22.8.4 Mergers and Acquisitions
    22.8.5 Certifications
    22.9 Medtronic plc
    22.9.1 Financial Analysis
    22.9.2 Product Portfolio
    22.9.3 Demographic Reach and Achievements
    22.9.4 Mergers and Acquisitions
    22.9.5 Certifications
    22.10 Novartis AG
    22.10.1 Financial Analysis
    22.10.2 Product Portfolio
    22.10.3 Demographic Reach and Achievements
    22.10.4 Mergers and Acquisitions
    22.10.5 Certifications
    22.11 Glaxo SmithKline Plc
    22.11.1 Financial Analysis
    22.11.2 Product Portfolio
    22.11.3 Demographic Reach and Achievements
    22.11.4 Mergers and Acquisitions
    22.11.5 Certifications
    23 Cancer Pain Market- Distribution Model (Additional Insight)
    23.1 Overview
    23.2 Potential Distributors
    23.3 Key Parameters for Distribution Partner Assessment
    24 Key Opinion Leaders (KOL) Insights (Additional Insight)
    25 Company Competitiveness Analysis (Additional Insight)
    25.1 Very Small Companies
    25.2 Small Companies
    25.3 Mid-Sized Companies
    25.4 Large Companies
    25.5 Very Large Companies
    26 Payment Methods (Additional Insight)
    26.1 Government Funded
    26.2 Private Insurance
    26.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Request A Sample
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us